Revision consensus haemophilia: Treatment and responsibility;Herziening consensus hemofilie: Behandeling en verantwoordelijkheid

Nederlands Tijdschrift voor Geneeskunde

Volumn 141, Issue 52, 1997, Pages 2566-2571

  Briet E ^a   Mauser Bunschoten, E P ^b   Van Everdingen, J J E ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Centraal Begeleidingsorgaan V I   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD CLOTTING DISORDER; HEMOPHILIA; HOSPITALIZATION; PROPHYLAXIS; TREATMENT PLANNING; VIRUS INACTIVATION; VIRUS INFECTION; X CHROMOSOME LINKAGE;

BLOOD-BORNE PATHOGENS; COMBINED MODALITY THERAPY; COST OF ILLNESS; CROSS INFECTION; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; VON WILLEBRAND DISEASE;

EID: 0031588422     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiency. In: Colman RW, Hirsch J, Marder VJ, Salzman EW, editors. Haemostasis and thrombosis. 3rd ed. Toronto. Lippincott, 1994.
2. Bloom AL. The management of patients with inherited blood coagulation disorders. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Hemostasis and thrombosis. 3rd ed. Edinburgh: Churchill Livingstone, 1994.
3. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991;13 280-7.
4. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prohylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
5. Mauser-Bunschoten EP. Complications of hemophilia care [proefschrift]. Utrecht: Universiteit Utrecht, 1995.
6. Mauser-Bunschoten EP, Bresters D, Drimmelen AA van, Roosendaal G, Cuypers HT, Reesink HW, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995; 45:241-6.
7. Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994,120:1-7.
8. Peerlinck K, Vermylen J Acute hepatitis in patients with haemophilia A [letter]. Lancet 1993;341:179.
9. Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products [letter]. Thromb Haemost 1994;72:162-4.
10. Rosendaal FR, Nieuwenhuis HK, Berg HM van den, Heijboer H, Mauser-Bunschoten EP, Meer J van der, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Dutch Hemophilia Study Group. Blood 1993;81:2180-6.
11. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Berg HM van den. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995;86:983-8.
12. Brackmann HH. The treatment of inhibitors against factor VIII by continuous treatment with factor VIII and activated prothrombin complex concentrates. In: Mariani G, Russo MA, Mandelli F, editors. Activated prothrombin complex concentrates. New York: Preager, 1982:194-205.
13. Standards and criteria for the care of persons with congenital bleeding disorders. New York: National Hemophilia Foundation, 1994.
14. Overzicht van de Bloedtransfusie in Nederland 1994. Amsterdam: College voor de Bloedtransfusie van het Nederlandse Rode Kruis, 1996.
15. Rosendaal FR. Hemophilia: the best of times, the worst of times [proefschrift]. Leiden: Rijksuniversiteit Leiden, 1989.